Xiantong Pharma opens Hong Kong IPO at up to HK$446m
Xiantong Pharmaceutical is seeking up to HK$446m in a Hong Kong IPO of 6.56m shares at HK$52 to HK$68 each, a small test of appetite for clinical-stage Chinese biotech.
What happened
Xiantong Pharmaceutical, ticker 09941.HK, began taking orders on 16 November for an IPO of 6.56m H shares at HK$52 to HK$68 each. The offer closes on 19 November, pricing is due by 20 November and trading is expected on 24 November. GF Securities, CICC and CITIC Securities are joint sponsors.
The numbers
| Item | Detail |
|---|---|
| Shares offered | 6.56m H shares |
| Price range | HK$52 to HK$68 |
| Maximum proceeds | HK$446m |
| Order period | 16 to 19 November |
| Pricing | By 20 November |
| Expected trading | 24 November |
Why it matters
Xiantong develops radiopharmaceuticals for cancer diagnostics and therapy. The niche has drawn strategic and venture money but has few Hong Kong comparables, so the float will be priced largely on narrative and pipeline rather than on a peer set.
The counter-argument is that a HK$446m deal is too small to prove the market for clinical-stage Chinese biotech; it may price on scarcity rather than on demand. Still, a clean float would give other radiopharma groups a route, and a weak one would confirm that investors will fund only assets with near-term catalysts.
What to watch
- Final pricing and cornerstone participation.
- First-day trading on 24 November.
- Pipeline timelines and cash runway disclosed in the prospectus.
Original source: Stockstar · 16 Nov 2026
